Cargando…

Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States

Detalles Bibliográficos
Autores principales:	Mougalian, Sarah S., Kish, Jonathan K., Zhang, Jingchuan, Liassou, Djibril, Feinberg, Bruce A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107069/ https://www.ncbi.nlm.nih.gov/pubmed/33826091 http://dx.doi.org/10.1007/s12325-021-01683-0

Ejemplares similares

Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States
por: Mougalian, Sarah S., et al.
Publicado: (2021)

Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States
por: Kish, Jonathan K., et al.
Publicado: (2020)

Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting
por: Mougalian, Sarah S., et al.
Publicado: (2018)

Comparative Effectiveness of Palliative Chemotherapy in Metastatic Breast Cancer: A Real‐World Evidence Analysis
por: Feinberg, Bruce, et al.
Publicado: (2020)

Correction to: Real-World Treatment Patterns in Patients with Vitiligo in the United States
por: Rosmarin, David, et al.
Publicado: (2023)

P1057: REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE
por: Harrison, C., et al.
Publicado: (2022)

Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
por: Hattori, Masaya, et al.
Publicado: (2017)

Correction to: Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine
por: Kazmi, Shayma, et al.
Publicado: (2021)

Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody–Drug Conjugate Therapy
por: Goyal, Ravi K, et al.
Publicado: (2023)

P1060: REAL-WORLD CLINICAL OUTCOMES AFTER 3 AND 6 MONTHS OF TREATMENT WITH FEDRATINIB FOLLOWING RUXOLITINIB FAILURE
por: Mascarenhas, J., et al.
Publicado: (2022)

Real-world effect of bevacizumab and eribulin on metastatic breast cancer using a propensity score matching analysis
por: Matsui, Koshi, et al.
Publicado: (2023)

High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real‐World Administrative Claims Analysis of Statin‐Treated Patients With High Residual Cardiovascular Risk
por: Toth, Peter P., et al.
Publicado: (2018)

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life
por: Garrone, Ornella, et al.
Publicado: (2016)

Correction: Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States
por: Hess, Lisa M., et al.
Publicado: (2023)

Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study
por: Zhao, Yannan, et al.
Publicado: (2021)

Correction to: Investigating diagnosis, treatment, and burden of disease in patients with ankylosing spondylitis in Central Eastern Europe and the United States: a real‑world study
por: Korotaeva, T., et al.
Publicado: (2022)

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

Predictors of Nutritional Deficiencies After Bariatric Surgery in the United States: Analysis of Real-World Data
por: Ba, Djibril, et al.
Publicado: (2022)

Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Kim, Stephanie I., et al.
Publicado: (2021)

Correction: Real-world effectiveness of osteoporosis treatments in Germany
por: O’Kelly, James, et al.
Publicado: (2022)

P515: A REAL-WORLD EVALUATION OF TREATMENT PATTERNS AND OUTCOMES OF ACUTE MYELOID LEUKEMIA INDUCTION THERAPIES IN THE COMMUNITY SETTING
por: Maher, Keri, et al.
Publicado: (2023)

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
por: Wilks, Sharon, et al.
Publicado: (2015)

Effectiveness, safety, and impact on quality of life of eribulin‐based therapy in heavily pretreated patients with metastatic breast cancer: A real‐world analysis
por: Gui, Xinyu, et al.
Publicado: (2023)

Correction: Eribulin rapidly inhibits TGF-β-induced Snail expression and can induce Slug expression in a Smad4-dependent manner
por: Kaul, Roma, et al.
Publicado: (2020)

Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States
por: Verstovsek, Srdan, et al.
Publicado: (2020)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Correction to: Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience
por: Rose, Tracy L., et al.
Publicado: (2022)

Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review
por: Watanabe, Junichiro
Publicado: (2015)

Pharmacodynamic analysis of eribulin safety in breast cancer patients using real‐world postmarketing surveillance data
por: Kawamura, Takahisa, et al.
Publicado: (2018)

Author Correction: The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan
por: Yamamoto, Shun, et al.
Publicado: (2022)

Correction: Regulation of E-cadherin localization by microtubule targeting agents: rapid promotion of cortical E-cadherin through p130CAS/Src inhibition by eribulin
por: Dybdal-Hargreaves, Nicholas F., et al.
Publicado: (2019)

A Letter in Support of Real-World RECIST
por: Gajra, Ajeet, et al.
Publicado: (2020)

Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States
por: Galsky, Matthew D., et al.
Publicado: (2018)

Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
por: Aogi, Kenjiro, et al.
Publicado: (2021)

Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
por: Aogi, Kenjiro, et al.
Publicado: (2022)

Author Correction: The State of the World’s Beaches
por: Luijendijk, Arjen, et al.
Publicado: (2018)

Correction: Carotid Artery Stenting: A Single Center “Real World” Experience
por: Krasniqi, Nazmi, et al.
Publicado: (2012)

Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes
por: Kobayashi, Eisuke, et al.
Publicado: (2019)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy
por: Doherty, Mark K, et al.
Publicado: (2015)

Correction: Regional models of genetic services in the United States
por: Kaye, Celia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_218c0db9va33q6pknaufloar9h